POC Study in Partially Responsive Generalized Anxiety Disorder
NCT02310568
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Outpatient males and females 18 65 years of age (inclusive).
2. Diagnostic and Statistical Manual of Mental Disorders Fourth edition Text Revised (DSM IV TR) diagnosis of GAD (DSM IV TR, 300.02), confirmed as primary diagnosis by the Mini international neuropsychiatric interview (MINI) structured interview.
3. All subjects must have a total HAM A (via SIGH A) score 22 at screening. In addition, scores at the baseline visit must also be within 20% of scores at screening.
4. Subjects must also have a Covi Anxiety Scale score of 9 and a Raskin Depression Scale score 7 at the Screening (Visit 1) visit to ensure predominance of anxiety symptoms over depression symptoms.
5. Taking an FDA approved GAD treatment (escitalopram 10 to 20 mg total daily dose, paroxetine 20 to 50 mg total daily dose, duloxetine 60 to 120 mg total daily dose, or venlafaxine 75 to 225 mg total daily dose) at a stable FDA approved dosage for at least the two consecutive months in the current episode immediately prior to the screening visit. Sertraline or citalopram are also permitted as background treatment for GAD at doses of 50 to 200 mg total daily dose and 20 to 40 mg total daily dose, respectively.
1. Subjects with a history of daily benzodiazepine use within one month of the screening
visit.
2. Recent (defined as meeting disorder diagnostic criteria during the last 6 months) of a
DSM IV TR Axis I diagnosis other than generalized anxiety disorder, with the following
exceptions: a. Subjects with recent (in the last 2 months) major depressive disorder
may be enrolled if the anxiety symptoms are predominant over the depressive symptoms,
as judged by the Covi/Raskin criteria listed above and confirmed GAD as the primary
diagnosis by the MINI structured interview. b. Comorbid social phobia and/or specific
phobias are permitted as long as the anxiety symptoms due to these disorders are
clinically less significant than the anxiety symptoms due to GAD and GAD is confirmed
as the primary diagnosis by the MINI structured interview.
3. Recent (defined as meeting disorder diagnostic criteria during the last 6 months) of a
DSM IV TR Axis I of panic disorder with or without agoraphobia, Post Traumatic Stress
Disorder (PTSD), dissociative disorder, obsessive compulsive disorder, attention
deficit disorder. If a subject has a past misdiagnosis of any of these disorders, or
if the subject has another psychiatric disorder that in the opinion of the
investigator affects the suitability of a subject for this study based on safety or
other considerations, the investigator will need to contact the sponsor prior to
screening.
4. Past and/or current DSM IV TR diagnosis of schizophrenia, schizoaffective disorder,
other psychotic disorders, bipolar disorders (I or II), factitious disorder or
cognitive disorder (including delirium, dementia, and amnestic disorder).
5. Presence of comorbid personality disorders (Axis II) based on DSM IV TR.
6. Subjects who meet DSM IV TR defined diagnostic criteria for psychoactive substance
dependence (excluding nicotine dependence) within 12 months of screening or DSM IV TR
defined substance abuse within 3 months prior to screening.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New Haven, Connecticut
- New Haven, Connecticut
- Orlando, Florida
- Prairie Village, Kansas
- Birmingham, Alabama
- Litchfield Park, Arizona
- Arcadia, California
- Beverly Hills, California
- Costa Mesa, California
- Costa Mesa, California
- Encino, California
- Escondido, California
- Murrieta, California
- National City, California
- Newport Beach, California
- Orange, California
- Pasadena, California
- Redlands, California
- San Diego, California
- San Diego, California
- Sherman Oaks, California
- Temecula, California
- Upland, California
- Wildomar, California
- Denver, Colorado
- Hamden, Connecticut
- Norwich, Connecticut
- Altamonte Springs, Florida
- Ft. Myers, Florida
- Jacksonville, Florida
- Maitland, Florida
- Miami, Florida
- Miami, Florida
- Orange City, Florida
- Orlando, Florida
- South Miami, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Marietta, Georgia
- Libertyville, Illinois
- Naperville, Illinois
- Park Ridge, Illinois
- Greenwood, Indiana
- Terre Haute, Indiana
- Overland Park, Kansas
- Prairie Village, Kansas
- Wichita, Kansas
- Owensboro, Kentucky
- Lake Charles, Louisiana
- Baltimore, Maryland
- Belmont, Massachusetts
- Boston, Massachusetts
- Fall River, Massachusetts
- Haverhill, Massachusetts
- Pittsfield, Massachusetts
- Omaha, Nebraska
- Las Vegas, Nevada
- Nashua, New Hampshire
- Albuquerque, New Mexico
- Bronx, New York
- Brooklyn, New York
- New York, New York
- New York, New York
- New York, New York
- Rochester, New York
- Raleigh, North Carolina
- Columbus, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Toledo, Ohio
- Bethany, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Portland, Oregon
- Salem, Oregon
- Allentown, Pennsylvania
- Media, Pennsylvania
- Norristown, Pennsylvania
- Philadelphia, Pennsylvania
- Lincoln, Rhode Island
- Columbia, South Carolina
- Memphis, Tennessee
- Memphis, Tennessee
- Austin, Texas
- Dallas, Texas
- Dallas, Texas
- DeSoto, Texas
- Houston, Texas
- Houston, Texas
- Lake Jackson, Texas
- San Antonio, Texas
- Woodstock, Vermont
- Charlottesville, Virginia
- Seattle, Washington
- Middleton, Wisconsin
- Waukesha, Wisconsin
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | POC Study in Partially Responsive Generalized Anxiety Disorder | |||
Official Title ICMJE | An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder | |||
Brief Summary | This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Generalized Anxiety Disorder | |||
Intervention ICMJE | Drug: PF-06372865.
Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration. | |||
Study Arms ICMJE |
| |||
Publications * | Targum SD, Murphy C, Khan J, Zumpano L, Whitlock M, Simen AA, Binneman B. Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder. Innov Clin Neurosci. 2018 Apr 1;15(3-4):37-42. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 90 | |||
Original Estimated Enrollment ICMJE | 384 | |||
Actual Study Completion Date ICMJE | October 2015 | |||
Actual Primary Completion Date | October 2015 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion criteria:
Exclusion criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02310568 | |||
Other Study ID Numbers ICMJE | B7431007 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2016 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |